Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Cotadutide

Stage Phase 1Stale

Sponsor AstraZeneca

Route injection

Class GLP-1/glucagon

Mechanism dual GLP-1 and glucagon receptor agonist

Sources

registry, as of 2023-11-07Stale

https://clinicaltrials.gov/study/NCT05437848

Chinese Multiple Dose Escalation (MDE) High Dose Study. Overall status COMPLETED. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 16. Conditions Diabetes. A Phase 1 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cotadutide in Overweight/Obese Subjects with Chinese ancestry with Type 2 Diabetes Mellitus

ClinicalTrials.gov NCT05437848 protocol and results modules

registry, as of 2020-07-31Stale

https://clinicaltrials.gov/study/NCT04208620

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus. Overall status COMPLETED. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 16. Conditions Type 2 Diabetes. This is a Phase 1 study designed to assess the safety and tolerability of MEDI0382 (Cotadutide) in Japanese T2DM patients.

ClinicalTrials.gov NCT04208620 protocol and results modules

publication, as of 2021-11-11Stale

https://pubmed.ncbi.nlm.nih.gov/34016612/

Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were e

PMID 34016612

Studies

COTA China PK

Registry NCT05437848

Phase Phase 1

Status Completed

Enrollment 16

Start 2022-02-25

Primary completion 2022-12-12

Study completion 2022-12-12

Cotadutide

Regimen once daily

Comparator placebo

Population Diabetes

Placebo

Regimen once daily

Population Diabetes

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

Registry NCT04208620

Phase Phase 1

Status Completed

Enrollment 16

Start 2020-01-21

Primary completion 2020-07-08

Study completion 2020-07-08

Placebo

Population Type 2 Diabetes

Cotadutide

Comparator placebo

Population Type 2 Diabetes